Immutep Limited (IMMP)
Immutep Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Immutep Limited (IMMP) is a Biotechnology company based in AU with a market capitalization of $58.8M. Revenue grew 31.3% year-over-year and free cash flow was negative at -$43.1M. This page tracks IMMP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
AU · 41 employees · IPO Apr 19, 2012
Valuation
Valuation & price
$0.45as of May 26, 2026· -85.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$58.8M
Market cap
31.3%
Revenue growth (YoY)
-1117.5%
Gross margin
-$43.1M
Free cash flow (USD)
-$128.1M
Net debt
Net cash position
21.3%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed May 1, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Immutep Limited's market cap?
Immutep Limited (IMMP) has a market capitalization of $58.8M.
What is IMMP's P/E ratio?
A meaningful P/E ratio is not available for IMMP — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying IMMP stock?
SEC Form 4 filings show no open-market insider buys at Immutep Limited in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.